AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 92 min read$ABEO

Seshadri Vishwas sold $473K of ABEO

Seshadri Vishwas (Chief Executive Officer) sold 67,971 shares of ABEONA THERAPEUTICS INC. (ABEO) at $6.96 ($0.47M total) on 2026-07-09.

Original reporting
SEC EDGAR · Seshadri Vishwas
Published Jul 9, 2026, 11:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 9, 2026, 11:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ABEO
Neutral
medium confidence
Mentioned
$ABEO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABEONeutralLow
01

Why it matters

The newest fact is the CEO’s open-market sale of 67,971 shares at $6.9637 on 2026-07-09, totaling $473,329.65.

02

Market read

Traders may monitor ABEO for additional insider activity, but the filing alone does not provide new operational or financial guidance.

03

What to watch

No 10b5-1 plan is mentioned, but the article also provides no context on prior sales, option exercises, tax events, or planned future transactions.

Relevance 4/10Novelty 5/10Timing: Filed 2026-07-09 after-hours (Form 4 timestamp 19:22:41-04:00).

Background

This is an SEC Form 4 insider transaction disclosure for ABEONA THERAPEUTICS INC. (ABEO).

Company-level read

Ticker impact

$ABEONeutralMedium confidence
Context

ABEO CEO Seshadri Vishwas sold 67,971 shares in an open-market transaction for about $473K, per a same-day Form 4 filing.

Expected impact

Likely limited, short-lived impact unless follow-on selling or other disclosures emerge.

Evidence & confidence

The filing is a routine insider sale with no 10b5-1 plan stated and no accompanying company-specific operational update in the text.

Market effects

Sector

Minimal, as this is company-specific insider activity with no sector-wide catalyst described.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be for diversification or liquidity needs and may not signal reduced confidence, especially without evidence of a broader pattern.

Key entities

  • issuer
    ABEO

    Abeona Therapeutics Inc., the company whose CEO insider sale is disclosed.

  • insider
    Seshadri Vishwas

    Chief Executive Officer and director reporting the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ABEO insider trading history →

Related articles

SEP 26
$ABEOMed

Abeona, NexGen, Nano Nuclear, SanDisk, Tempus Trending

Analysts initiated coverage on five stocks: Abeona (ABEO) with a $17 target, NexGen (NXE) at $14, Nano Nuclear (NNE) at $33, SanDisk (SNDK) at $2,400, and Tempus (TEM) at $75. Abeona's ZEVASKYN gene therapy, NexGen's uranium project, Nano Nuclear's KRONOS reactor, SanDisk's AI infrastructure, and Tempus's diagnostics business are key focuses.

tipranks.com3 min
SEP 18
$ABEOHighAI 9/10

Abeona Therapeutics Inc.: Abeona Therapeutics Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

Abeona Therapeutics (ABEO) congratulated Ultragenyx (RARE) on FDA approval of FAYUVI, a gene therapy for Sanfilippo syndrome type A (MPS IIIA). Abeona initially developed the therapy and licensed it to Ultragenyx in 2022, making it eligible for milestone payments and royalties. FAYUVI addresses a rare, progressive neurodegenerative disease with high unmet medical need.

finanznachrichten.de2 min
AUG 13
$ABEOMed

Abeona Therapeutics Swings To Q2 Net Loss; Shares Plunge

Abeona Therapeutics (ABEO) reported Q2 2026 results showing a swing to a net loss of $20.19M, or $0.35/share, versus net income of $108.83M, or $1.71/share, a year earlier largely due to a $152.37M priority review voucher gain. Q2 revenue rose to $11.38M from $0.40M. Cash totaled $146.8M as of June 30. ZEVASKYN treated 5 patients in Q2.

rttnews.com4 min